卖什么
Biotech developing iPS-cell-derived oocyte and ovarian somatic cells for fertility treatment (pipelines DIOS-001 and DIOS-101).
商业模式拆解
触发点：什么让他们现在购买？
Age-related decline in egg and sperm function lowering pregnancy odds; DIOS-001 targets better pregnancy rate through in-vitro oocyte maturation.
工作流：什么输入变成什么输出？
Directed differentiation of iPS cells into oocytes and ovarian somatic cells for infertility solutions.
渠道：怎么接触到客户？
Pre-commercial; contact form, investors listed (ANRI, etc.); Nature-published technology and own patent.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| 2026-06-12 | A 轮 | 10億円超 | — | news.google.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.